Results 151 to 160 of about 20,409 (197)
Some of the next articles are maybe not open access.
Treatment with Interferons (including Pegylated Interferons) in Patients with Hepatitis B
Seminars in Liver Disease, 2004Studies of 4 to 6 months of treatment with interferon for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection have shown clearance of HBeAg to be higher in treated patients than it is in controls by approximately 25%. These results are considerably better than those with antiviral agents.
openaire +4 more sources
Pegylated Interferons for the Treatment of Chronic Hepatitis B
Recent Patents on Anti-Infective Drug Discovery, 2006Five drugs are approved for the treatment of chronic hepatitis B: conventional interferon (IFN) alfa, lamivudine, adefovir dipivoxil, pegylated interferon (peginterferon) alfa-2a and entecavir. Conventional IFN monotherapy has a narrow range of efficacy, should be administered subcutaneously and is commonly associated with adverse effects.
Chun-Jen, Liu, Jia-Horng, Kao
openaire +2 more sources
Reviews in gastroenterological disorders, 2002
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire +1 more source
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire +1 more source
CNS Drugs, 2012
Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are ...
Bernd C, Kieseier, Peter A, Calabresi
openaire +2 more sources
Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are ...
Bernd C, Kieseier, Peter A, Calabresi
openaire +2 more sources
Pegylated Interferon Monotherapy for Chronic Hepatitis C
Seminars in Liver Disease, 2004Interferon (IFN) alpha-2a has been attached to a branched 40-kD PEG molecule and IFN alpha-2b to a linear 12-kD PEG molecule leading to elimination half-lives of approximately 75 and approximately 30 hours, respectively. In one pivotal trial, 531 patients with chronic hepatitis C were assigned to receive either 180 microg of pegylated IFN alpha-2a once
Jenny, Heathcote, Stefan, Zeuzem
openaire +2 more sources
Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?
Digestive Diseases and Sciences, 2007Currently, there are limited therapeutic options available for chronic hepatitis C (HCV) patients who fail treatment with peginterferon alpha (PEG IFN) + ribavirin (RBV). An option is retreatment with a second course PEG-IFN + RBV. However, the virologic clearance with this option is unknown.
Rekha, Cheruvattath +5 more
openaire +2 more sources
Treatment of cirrhotic patients in the pegylated interferon era
Digestive and Liver Disease, 2004Chronic hepatitis C is a leading cause of cirrhosis, hepatocellular carcinoma, digestive tract haemorrhage and hepatic insufficiency. The present best strategy to prevent severe complications of chronic hepatitis C is the decrease of fibrosis progression. Recently, pegylated interferon combination treatments of chronic hepatitis C have made it possibly
openaire +2 more sources
Pegylation of Interferon Alfa: Structural and Pharmacokinetic Properties
Seminars in Liver Disease, 2003The attachment of a polyethylene glycol (PEG) polymer to a protein or peptide is becoming increasingly common within the pharmaceutical industry as a way of altering the activity of the parent molecule. Significant improvements in biological activity with PEG molecules have been seen with several licensed drugs, allowing for product life cycle ...
openaire +2 more sources
Emerging strategies for pegylated interferon combination therapy
Nature Clinical Practice Gastroenterology & Hepatology, 2007Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication.
openaire +2 more sources